Control of type 2 diabetes mellitus in Spain today: Identification of the main obstacles in daily clinical practice;Situación actual del control de la diabetes mellitus tipo 2 en España. Identificación de las principales barreras en la práctica clínica diaria

Medicina Clinica

Volumn 141, Issue SUPPL. 2, 2013, Pages 3-6

  Torres, Irene Vinagre ^a   Donlo, Ignacio Conget ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Clinical inertia; Metabolic control; Spain; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; NEW DRUG;

ARTICLE; CLINICAL PRACTICE; DIABETES CONTROL; DIABETIC PATIENT; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HUMAN; NATIONAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; SPAIN;

CLINICAL INERTIA; CONTROL METABÓLICO; DIABETES MELLITUS TIPO 2; ESPAÑA; INERCIA TERAPÉUTICA; METABOLIC CONTROL; SPAIN; TYPE 2 DIABETES MELLITUS;

ANTIHYPERTENSIVE AGENTS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG SUBSTITUTION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; SPAIN;

EID: 84893081086     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(13)70056-3     Document Type: Article

References (30)

1. Conget I. Diagnosis, classification and cathogenesis of diabetes mellitus. Rev Esp Cardiol. 2002;55:528-35.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
3. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95.
4. Elbein SC. Perspective: the search for genes for type 2 diabetes in the post-genome era. Endocrinology. 2002;143:2012-8.
5. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-72.
6. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature. 2001;414:788-91.
7. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363: 2339-50.
8. Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 1998;92:593-6.
9. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest. 2002;32 Suppl 3:35-45.
10. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46:3-19.
11. Conget I. Diagnosis, classification and cathogenesis of diabetes mellitus. Rev Esp Cardiol. 2002;55:528-35.
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
13. Conget I, Giménez M. Glucose control and cardiovascular disease: is it important? No. Diabetes Care. 2009;32 Suppl 2:S334-6.
14. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-98.
15. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@ bet.es Study. Diabetologia. 2012;55:88-93.
16. Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care. 2004;27:2616-21.
17. Mata-Cases M, Roura-Olmeda P, Berenguer-Iglesias M, Birulés-Pons M, Mundet- Tuduri X, Franch-Nadal J, et al. Fifteen years of continuous improvement of quality care of type 2 diabetes mellitus in primary care in Catalonia, Spain. Int J Clin Pract. 2012;66:289-98.
18. Orozco-Beltrán D, Gil-Guillén VF, Quirce F, Navarro-Pérez J, Pineda M, Gomez-dela- Cámara A, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007;61:909-15.
19. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care. 2012;35:774-9.
20. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135:825-34.
21. López-Simarro F, Brotons C, Moral I, Cols-Sagarra C, Selva A, Aguado-Jodar A, et al. Inertia and treatment compliance in patients with type 2 diabetes in primary care. Med Clin (Barc ) 2012;138:377-84.
22. El-Kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS. Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999;22:1617-20.
23. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-40.
24. Conthe P, Mata M, Orozco D, Pajuelo F, Barreto CS, Anaya SF, et al. Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain. Diabetes Res Clin Pract. 2011;91:108-14.
25. Grant R, Adams AS, Trinacty CM, Zhang F, Kleinman K, Soumerai SB, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30:807-12.
26. Parchman ML, Pugh JA, Romero RL, Bowers KW. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med. 2007;5: 196-201.
27. Franch NJ, Artola MS, Díez EJ, Mata CM. The evolution of quality care indicators of patients with type 2 diabetes in the Spanish primary care (1996-2007). The RedGEDAPS quality of care program. Med Clin (Barc). 2010;135:600-7.
28. Olveira-Fuster G, Olvera-Márquez P, Carral-Sanlaureano F, González-Romero S, Aguilar-Diosdado M, Soriguer-Escofet F. Excess hospitalizations, hospital days, and inpatient costs among people with diabetes in Andalusia, Spain. Diabetes Care. 2004;27:1904-9.
29. Mata M, Antoñanzas F, Tafalla M, Sanz P. The cost of type 2 diabetes in Spain: the CODE-2 study. Gac Sanit. 2002;16:511-20.
30. Costi M, Smith H, Reviriego J, Castell C, Goday A, Dilla T. Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study. Endocrinol Nutr. 2011;58:274-82.